Nifuroxazide Mitigates Angiogenesis in Ehlrich’s Solid Carcinoma: Molecular Docking, Bioinformatic and Experimental Studies on Inhibition of Il-6/Jak2/Stat3 Signaling

Nifuroxazide Mitigates Angiogenesis in Ehlrich’s Solid Carcinoma: Molecular Docking, Bioinformatic and Experimental Studies on Inhibition of Il-6/Jak2/Stat3 Signaling

Nifuroxazide is an antidiarrheal medication that has promising anticancer activity against diverse types of tumors. The present study tested the anticancer activity of nifuroxazide against Ehrlich’s mammary carcinoma grown in vivo. Furthermore, we investigated the effect of nifuroxazide on IL-6/jak2...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Mohamed El-Sherbiny, Rehab M. El-Sayed, Mohamed A. Helal, Afaf T. Ibrahiem, Hoda S. Elmahdi, Mohamed Ahmed Eladl, Shymaa E. Bilay, Asma M. Alshahrani, Mona K. Tawfik, Ziad E. Hamed, Amany O. Mohamed, Sawsan A. Zaitone
Formato: article
Lenguaje:EN
Publicado: MDPI AG 2021
Materias:
angiogenesis
bioinformatics
Ehrlich’s solid tumors
molecular docking
IL-6/Jak2/STAT3 signaling
nifuroxazide
Organic chemistry
QD241-441
Acceso en línea:https://doaj.org/article/93dbed2281304f2aba06c3ade34e5b39
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Internet

https://doaj.org/article/93dbed2281304f2aba06c3ade34e5b39

Ejemplares similares